VBIV — VBI Vaccines Income Statement
0.000.00%
Last trade - 00:00
- $13.63m
- $28.47m
- $1.08m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.35 | 2.22 | 1.06 | 0.631 | 1.08 |
Cost of Revenue | |||||
Gross Profit | -1.15 | -5.68 | -8.11 | -10.1 | -10.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 63.8 | 54.6 | 44.7 | 68.7 | 83.1 |
Operating Profit | -60.4 | -52.4 | -43.6 | -68 | -82 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -63.6 | -54.8 | -46.2 | -69.8 | -113 |
Provision for Income Taxes | |||||
Net Income After Taxes | -63.6 | -54.8 | -46.2 | -69.8 | -113 |
Net Income Before Extraordinary Items | |||||
Net Income | -63.6 | -54.8 | -46.2 | -69.8 | -113 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -63.6 | -54.8 | -46.2 | -69.8 | -113 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -26.2 | -12.2 | -6.35 | -8.21 | -13.1 |